ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Alberta Health services

Status: Completed

Conditions: Peripheral Stem Cell/Marrow Transplant

Treatments: Drug: G-CSF/Filgrastim

Study type: Interventional

Funder types: Other

Identifiers

NCT00168168

HE-10-0053

Details and patient eligibility

About

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• over age 18
• autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular

Exclusion criteria

• age below 18 years
• sensitive to G-CSF

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind